CTIS2023-506596-10-00进行中（未招募）1 期
GFC-BEMD-01-NXP/23
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 42
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
Randomised, relative bioavailability clinical trial of amylmetacresol, dichlorobenzyl alcohol, lidocaine and vitamin c lozenges after a single oral dose administration to healthy volunteers under fasting conditions in a crossover design.healthy volunteerCTIS2023-507599-34-00Geiser Pharma S.L.60
进行中（未招募）
1 期
A study to characterize the safety, efficacy, pharmacokinetics of subcutaneous administration of ABBV-383 in patients with relapsed or refractory Multiple MyelomaCTIS2023-507901-32-00AbbVie Deutschland GmbH & Co. KG55
进行中（未招募）
1 期
Conducting a quality study of the medicinal product - Vortioxetineo therapeutic indication in the current trial with healthy volunteers. The intended indication is for the treatment of major depressive episodes in adultsMedDRA version: 21.1Level: LLTClassification code: 10081270Term: Major depressive disorder Class: 10037175CTIS2023-509946-36-00CCDRD Cooperative Clinical Drug Research and Development AG36
招募中
1 期
A Phase 1b Study of Imvotamab in Severe Systemic Lupus ErythematosusSystemic Lupus ErythematosusCTIS2023-506499-29-00IGM Biosciences Inc.18
进行中（未招募）
1 期
Bioequivalence study of the oral suspension of netupitant/palonosetron combination product versus the hard capsules of netupitant/palonosetron combination product after a single dose administration to healthy male and female volunteers in an open-label, randomised, single centre, 2-treatment, 4-period, 2 sequence replicative desigHealthy volunteersCTIS2023-504355-28-03Helsinn Healthcare S.A.74